600 related articles for article (PubMed ID: 24563450)
1. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
Long EF; Swain GW; Mangi AA
Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ventricular assist device therapy as a bridge to transplantation compared with nonbridged cardiac recipients.
Alba AC; Alba LF; Delgado DH; Rao V; Ross HJ; Goeree R
Circulation; 2013 Jun; 127(24):2424-35. PubMed ID: 23697907
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.
Rogers JG; Bostic RR; Tong KB; Adamson R; Russo M; Slaughter MS
Circ Heart Fail; 2012 Jan; 5(1):10-6. PubMed ID: 22052901
[TBL] [Abstract][Full Text] [Related]
4. Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(3):1-60. PubMed ID: 27026798
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure.
Baras Shreibati J; Goldhaber-Fiebert JD; Banerjee D; Owens DK; Hlatky MA
JACC Heart Fail; 2017 Feb; 5(2):110-119. PubMed ID: 28017351
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation.
Chew DS; Manns B; Miller RJH; Sharma N; Exner DV
Can J Cardiol; 2017 Oct; 33(10):1283-1291. PubMed ID: 28941608
[TBL] [Abstract][Full Text] [Related]
7. A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective.
Lim HS; Shaw S; Carter AW; Jayawardana S; Mossialos E; Mehra MR
J Heart Lung Transplant; 2022 Feb; 41(2):174-186. PubMed ID: 34922821
[TBL] [Abstract][Full Text] [Related]
8. Heart transplant and left ventricular assist device costs.
Digiorgi PL; Reel MS; Thornton B; Burton E; Naka Y; Oz MC
J Heart Lung Transplant; 2005 Feb; 24(2):200-4. PubMed ID: 15701438
[TBL] [Abstract][Full Text] [Related]
9. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial.
Rogers JG; Butler J; Lansman SL; Gass A; Portner PM; Pasque MK; Pierson RN;
J Am Coll Cardiol; 2007 Aug; 50(8):741-7. PubMed ID: 17707178
[TBL] [Abstract][Full Text] [Related]
10. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.
Clegg AJ; Scott DA; Loveman E; Colquitt J; Hutchinson J; Royle P; Bryant J
Health Technol Assess; 2005 Nov; 9(45):1-132, iii-iv. PubMed ID: 16303098
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of continuous-flow left ventricular assist devices.
Neyt M; Van den Bruel A; Smit Y; De Jonge N; Erasmus M; Van Dijk D; Vlayen J
Int J Technol Assess Health Care; 2013 Jul; 29(3):254-60. PubMed ID: 23763844
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation.
Moreno SG; Novielli N; Cooper NJ
J Heart Lung Transplant; 2012 May; 31(5):450-8. PubMed ID: 22115674
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular assist devices: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2004; 4(3):1-69. PubMed ID: 23074453
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with ventricular assist device use in children.
Mahle WT; Ianucci G; Vincent RN; Kanter KR
Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
[TBL] [Abstract][Full Text] [Related]
15. Should patients 60 years and older undergo bridge to transplantation with continuous-flow left ventricular assist devices?
Allen JG; Kilic A; Weiss ES; Arnaoutakis GJ; George TJ; Shah AS; Conte JV
Ann Thorac Surg; 2012 Dec; 94(6):2017-24. PubMed ID: 22858277
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the ventricular assist device programme in the UK.
Sharples L; Buxton M; Caine N; Cafferty F; Demiris N; Dyer M; Freeman C
Health Technol Assess; 2006 Nov; 10(48):1-119, iii-iv. PubMed ID: 17134596
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
[TBL] [Abstract][Full Text] [Related]
19. Left ventricular assist device destination therapy versus extended criteria cardiac transplant.
Daneshmand MA; Rajagopal K; Lima B; Khorram N; Blue LJ; Lodge AJ; Hernandez AF; Rogers JG; Milano CA
Ann Thorac Surg; 2010 Apr; 89(4):1205-9; discussion 1210. PubMed ID: 20338335
[TBL] [Abstract][Full Text] [Related]
20. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH
J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
